Enanta Pharmaceuticals
ENTA
$12.37
Share price
-0.88%
Change (1 day)
-65.20%
Change (1 year)
Categories
P/S ratio for Enanta Pharmaceuticals (ENTA)
P/S ratio as of April 2024 (TTM): 3.55
According to Enanta Pharmaceuticals 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.55464. At the end of 2023 the company had a P/S ratio of 2.69.
P/S ratio history for Enanta Pharmaceuticals from 2013 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 2.69 | -77.16% |
| 2022 | 11.8 | -28.54% |
| 2021 | 16.5 | 98.3% |
| 2020 | 8.32 | 27.67% |
| 2019 | 6.51 | 12.81% |
| 2018 | 5.77 | -32.86% |
| 2017 | 8.60 | -32.26% |
| 2016 | 12.7 | 169.68% |
| 2015 | 4.71 | -38.15% |
| 2014 | 7.61 | -92.1% |
| 2013 | 96.3 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 3.79 | 6.50% | 🇺🇸 USA |
 Novartis NVS | 4.01 | 12.75% | 🇨🇭 Switzerland |
 AbbVie ABBV | 5.20 | 46.38% | 🇺🇸 USA |
 Vertex Pharmaceuticals VRTX | 10.4 | 192.84% | 🇺🇸 USA |
 Merck MRK | 5.53 | 55.53% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 2.00 | -43.84% | 🇺🇸 USA |